Stock comparison
IDEXX Laboratories
Krystal Biotech
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
KRYS
Krystal Biotech
Market cap
$8.83B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | KRYS | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 51C | IDXX |
| Benjamin Graham | 80A | 74D | IDXX |
| Philip Fisher | 75B | 74C | IDXX |
| Peter Lynch | 71B | 58C | IDXX |
| Joel Greenblatt | 83C | 59C | IDXX |
| Charlie Munger | 87A | 64D | IDXX |
| Terry Smith | 84A | 64D | IDXX |
Side-by-side metrics
| Metric | IDXX | KRYS |
|---|---|---|
| Market cap | $44.12B | $8.83B |
| P/E (TTM) | 39.0x | 39.9x |
| EV/EBIT | 31.6x | 52.9x |
| ROIC (TTM) | 40.66% | 13.85% |
| Gross margin | 62.05% | 92.79% |
| Net margin | 24.63% | 53.92% |
| Revenue CAGR 5y | 7.56% | - |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $8.83B+80%
- ROIC (TTM)40.66%vs 13.85%+66%
- EV/EBIT31.6xvs 52.9x+40%
KRYS leads on
- Debt / Equity0.0xvs 0.7x+100%
- Net margin53.92%vs 24.63%+54%
- Gross margin92.79%vs 62.05%+33%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.